NCT07082114: An ongoing trial by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
This trial is ongoing. It must report results 1 year, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07082114 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of HDM1002 Tablets Compared With Dapagliflozin in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 14, 2025 |
| Completion date | Feb. 16, 2027 |
| Required reporting date | Feb. 16, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 11, 2026 |
| Days late | None |